Dacarbazine (dacarbazine)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Dacarbazine, a synthetic analog of a naturally occurring purine precursor, is an antimetabolite antineoplastic agent.
USES: Dacarbazine is used to treat certain types of cancer, such as skin cancer and Hodgkin's disease. It is a cancer chemotherapy drug that is used to slow or stop cancer cell growth.
Generic name: dacarbazine
Pronunciation: (duh-KAR-buh-zeen)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Dacarbazine
Indications
The following indications are listed for Dacarbazine:
- Hodgkin's Lymphoma
- Metastatic Malignant Melanoma
Also known as: Anemia Lymphatica, Hodgkin's Disease.
Dosing
Dosage of dacarbazine must be based on the clinical and hematologic response and tolerance of the patient in order to obtain optimum therapeutic results with minimum adverse effects. Clinicians should consult published protocols for the dosage of dacarbazine and other chemotherapeutic agents and the method and sequence of administration.
Because dacarbazine is considered an antineoplastic agent of high emetic risk, antiemetic therapy for the prevention of acute and delayed emesis is recommended. (See Cautions: GI Effects.)
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Although there are no adequate and controlled studies to date in humans, dacarbazine has been shown to be teratogenic in rats when given at dosages 20 times the usual human dosage. Dacarbazine should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.
It is not known whether dacarbazine is distributed into milk. Because of the carcinogenic potential of dacarbazine in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.